deCode Genetics Inc.

https://www.decode.com

Headquartered in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using its unique expertise and population resources, deCODE has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer. deCODE employs its capabilities to develop DNA-based tests and personal genome scans to better understand individual risk and empower prevention. It also licenses its tests, intellectual property and analytical tools to partners, and provides comprehensive genotyping, sequencing and data analysis services to companies and research institutions around the globe. Through its CLIA- and CAP-certified laboratory deCODE offers DNA-based tests for gauging risk and empowering prevention of common diseases, including deCODE T2™ for type 2 diabetes; deCODE AF™ for atrial fibrillation and stroke; deCODE MI™ for heart attack; deCODE ProstateCancer™ for prostate cancer; deCODE Glaucoma™ for a major type of glaucoma; and deCODE BreastCancer, for the common forms of breast cancer. Through its pioneering personal genome analysis service deCODEme™, deCODE enables individuals to better understand their risk of dozens of common diseases and to learn about their ancestry and other traits. *

	Start	1998-01-01 existent
	Group	Amgen (Group)
	Industry	genomics/genetics

	Region	Reykjavík
	Country	Iceland
	City	n. a.
		Address record changed: 2020-12-02

Basic data	Employees	n. a.
	Currency	USD
	Annual sales	40,403,000 (revenue, consolidated (2007) 2007-12-31)
	Profit	-95,526,000 (2007-12-31)
	Cash	94,058,000 (2007-12-31)

		* Document for »About Section«:

		Record changed: 2024-02-12